130 related articles for article (PubMed ID: 7647577)
41. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
Mazziotti G; Formenti AM; Frara S; Olivetti R; Banfi G; Memo M; Maroldi R; Giubbini R; Giustina A
J Clin Endocrinol Metab; 2018 Mar; 103(3):956-964. PubMed ID: 29121201
[TBL] [Abstract][Full Text] [Related]
42. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Görres G; Kaim A; Otte A; Götze M; Müller-Brand J
Eur J Nucl Med; 1996 Jun; 23(6):690-2. PubMed ID: 8662104
[TBL] [Abstract][Full Text] [Related]
43. The effect of suppressive therapy of nontoxic diffuse goiter on serum levels of thyroxine, 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine.
Johansen K; Hansen JM; Perrild H; Skovsted L; Kampmann JP
Acta Med Scand Suppl; 1979; 624():25-30. PubMed ID: 284710
[TBL] [Abstract][Full Text] [Related]
44. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
[TBL] [Abstract][Full Text] [Related]
45. The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women.
Sajjinanont T; Rajchadara S; Sriassawaamorn N; Panichkul S
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S71-6. PubMed ID: 16858944
[TBL] [Abstract][Full Text] [Related]
46. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
[TBL] [Abstract][Full Text] [Related]
47. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.
Reverter JL; Colomé E; Holgado S; Aguilera E; Soldevila B; Mateo L; Sanmartí A
Endocrine; 2010 Jun; 37(3):467-72. PubMed ID: 20960170
[TBL] [Abstract][Full Text] [Related]
48. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
49. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
50. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
51. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
[TBL] [Abstract][Full Text] [Related]
52. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
Stall GM; Harris S; Sokoll LJ; Dawson-Hughes B
Ann Intern Med; 1990 Aug; 113(4):265-9. PubMed ID: 2375563
[TBL] [Abstract][Full Text] [Related]
53. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
Heijckmann AC; Huijberts MS; Geusens P; de Vries J; Menheere PP; Wolffenbuttel BH
Eur J Endocrinol; 2005 Jul; 153(1):23-9. PubMed ID: 15994742
[TBL] [Abstract][Full Text] [Related]
54. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.
Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC
J Affect Disord; 2001 Oct; 66(2-3):185-91. PubMed ID: 11578671
[TBL] [Abstract][Full Text] [Related]
55. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I; Fujimoto Y
Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
[TBL] [Abstract][Full Text] [Related]
56. [Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].
Erne P; Staub JJ; Althaus B; Fleig Y; Girard J
Schweiz Med Wochenschr; 1983 Dec; 113(50):1922-3. PubMed ID: 6420884
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.
Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A
J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483
[TBL] [Abstract][Full Text] [Related]
58. Serum thyroid hormone and thyrotropin levels in subjects from endemic goiter regions of New Guinea.
Chopra IJ; Hershman JM; Hornabrook RW
J Clin Endocrinol Metab; 1975 Feb; 40(2):326-33. PubMed ID: 1117981
[TBL] [Abstract][Full Text] [Related]
59. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
60. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay.
Spencer CA; Lai-Rosenfeld AO; Guttler RB; LoPresti J; Marcus AO; Nimalasuriya A; Eigen A; Doss RC; Green BJ; Nicoloff JT
J Clin Endocrinol Metab; 1986 Aug; 63(2):349-55. PubMed ID: 3088021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]